A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE-164)

Trial Profile

A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE-164)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-164
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 25 Sep 2017 Planned End Date changed from 1 Jul 2018 to 9 Sep 2019.
    • 25 Sep 2017 Planned primary completion date changed from 1 Jul 2018 to 9 Sep 2019.
    • 12 Sep 2017 Results of this trial (n=61, data cut-off date: Feb 10, 2017) and another trial (refer CTP: 700265393, n=77, data cut-off date: Jan 27, 2017) presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top